BioSpace News Archive

Strive Health, the national leader in value-based kidney care, today announced that Kavita Patel, M.D., has joined the company’s Board of Directors.

Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced the company has reached a licensing agreement with Biomm S.A. for BAT1706, its bevacizumab biosimilar, under which Biomm will have exclusive rights to distribute and market the drug in Brazil.

PCT’s Effectiveness and Reproducibility Impacts Research Results and Fills Critical Role in Achieving Important Insights for the Development of New and Improved COVID-19 Diagnostics and Therapeutics [17-December-2020] SOUTH EASTON, Mass. , Dec. 17, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and s

Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, has announced its next generation disposable EEG cap, NeuroCap™, will now be available to the pediatric market across the U.S.

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company is participating in Biotech Showcase Digital and BIO @ JPM. Both events will be held virtually and

A recently published study in Surgical Case Reports by Gregory Chernoff, M.D., F.R.C.S.(C) demonstrated the efficacy of a topical Nitric Oxide serum called N1o1, Nitric Oxide Activating Serum to improve vascularity in wound healing populations.

The COVID-19 pandemic is a global public health crisis that has placed an increased focus on the importance of vaccination.

Largest urology practice with 30+ locations and 90+ providers standardizes their practice with the Persona CT computed tomography system for advanced oncology treatment planning

First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and well-tolerated, Vasomune will initiate a Phase 2 proof-of-concept study to assess efficacy in patients with moderate-to-severe COVID-19 disease

The National Kidney Foundation (NKF), representing the more than 37 million adults in the U.S. with kidney disease, their families, and the professionals who care for them, believes that a key principle of ethical vaccine allocation must be that the